Novartis AG rose to fresh highs, scoring a beat-and-raise quarter and resulting in a boost in shares. Despite the primary goal of their drug Cosentyx missing in a Phase III Arteritis study, Novartis continued to thrive. This pharmaceutical giant acquired Regulus Therapeutics for $1.7 billion and, following this, saw an improvement in their RS Rating. The strong momentum maintained by Novartis has lead analysts to believe Novartis to be a top value and momentum stock for the long-term. After posting better-than-expected Q1 sales figures and raising their full year guidance, the Bull Theory in favor of investing in Novartis strengthened. Deutsche Bank increased their stock target to CHF115 due to optimism around the cancer drug Pluvicto. Novartis has also announced plans for a $23 billion investment in US facilities despite threats of Pharma Tariffs by the Trump administration. The completion of the acquisition of Regulus Therapeutics lead to a significant boost in biotech shares. Fitch kept Novartis at a strong rating for their leading position in the pharma industry and Novartis raised its 2025 guidance again to the top end of their prior range. The outlook on Novartis is very positive due to its stronghold in the biotech industry.
Novartis Stocks News Analytics from Tue, 29 Oct 2024 07:00:00 GMT to Thu, 03 Jul 2025 15:58:00 GMT -
Rating 7
- Innovation 8
- Information 6
- Rumor -4
